Picture loading failed.

Anti-ADPRC therapeutic antibody (Pre-made Modakafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Modakafusp alfa (formerly TAK 573 or TEV 48573) is a CD38 targeted antibody (IgG4) fused with attenuated interferon alpha (IFN-α), being developed by Takeda, through its wholly-owned subsidiary Millennium Pharmaceuticals, for the treatment of multiple myeloma and solid tumours.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-352-1mg 1mg Inquiry
GMP-Bios-ab-352-10mg 10mg Inquiry
GMP-Bios-ab-352-100mg 100mg Inquiry
GMP-Bios-ab-352-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ADPRC therapeutic antibody (Pre-made Modakafusp biosimilar,Whole mAb Fusion)
INN Name Modakafusp
TargetADPRC
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesTakeda
Conditions Approvedna
Conditions ActiveMultiple myeloma
Conditions Discontinuedna
Development Techna